Ultramicronized palmitoylethanolamide rescues learning and memory impairments in a triple transgenic mouse model of Alzheimer’s disease by exerting anti-inflammatory and neuroprotective effects

Caterina Scuderi, Maria Rosanna Bronzuoli, Roberta Facchinetti, Lorenzo Pace, Luca Ferraro, Kevin Donald Broad, Gaetano Serviddio, Francesco Bellanti, Giampaolo Palombelli, Giulia Carpinelli, Rossella Canese, Silvana Gaetani, Luca Steardo Jr, Luca Steardo and Tommaso Cassano

Abstract
In an aging society, Alzheimer’s disease (AD) exerts an increasingly serious health and economic burden. Current treatments provide inadequate symptomatic relief as several distinct pathological processes are thought to underlie the decline of cognitive and neural function seen in AD. This suggests that the efficacy of treatment requires a multitargeted approach. In this context, palmitoylethanolamide (PEA) provides a novel potential adjunct therapy that can be incorporated into a multitargeted treatment strategy. We used young (6-month-old) and adult (12-month-old) 3xTg-AD mice that received ultramicronized PEA (um-PEA) for 3 months via a subcutaneous delivery system. Mice were tested with a range of cognitive and noncognitive tasks, scanned with magnetic resonance imaging/magnetic resonance spectroscopy (MRI/MRS), and neurochemical release was assessed by microdialysis. Potential neuropathological mechanisms were assessed postmortem by western blot, reverse transcription–polymerase chain reaction (RT-PCR), and immunofluorescence. Our data demonstrate that um-PEA improves learning and memory, and ameliorates both the depressive and anhedonia-like phenotype of 3xTg-AD mice. Moreover, it reduces Aβ formation, the phosphorylation of tau proteins, and promotes neuronal survival in the CA1 subregion of the hippocampus. Finally, um-PEA normalizes astrocytic function, rebalances glutamatergic transmission, and restrains neuroinflammation. The efficacy of um-PEA is particularly potent in younger mice, suggesting its potential as an early treatment. These data demonstrate that um-PEA is a novel and effective promising treatment for AD with the potential to be integrated into a multitargeted treatment strategy in combination with other drugs. Um-PEA is already registered for human use. This, in combination with our data, suggests the potential to rapidly proceed to clinical use.

Introduction
Alzheimer’s disease (AD) is the primary cause of dementia in the elderly, but currently prescribed medications provide only modest and transient benefits to a subset of patients.

Histopathologically, the major features of AD include the extracellular accumulation of beta amyloid (Aβ) fibrils in senile plaques (SPs) and intraneuronal neurofibrillary plaques (NPs) in the brain. Aβ, a cleavage product of the amyloid precursor protein (APP), is believed to be the primary initiating event in the pathogenesis of AD. Aβ peptides, which are formed by the proteolytic cleavage of APP, aggregate into fibrils that form the core of the SPs. NPs are intracellular inclusions composed of hyperphosphorylated tau protein, which is normally localized in neuronal processes.

In addition to Aβ and NPs, other pathological hallmarks of AD include neuroinflammation and synaptic degeneration. Neuroinflammation is associated with the activation of microglia and astrocytes, which release pro-inflammatory cytokines that contribute to neuronal damage and cognitive decline.

Current treatments for AD are symptomatic, and do not address the underlying pathological processes. Therefore, there is a need for novel therapeutic targets that can address multiple aspects of the disease.

Palmitoylethanolamide (PEA) is a naturally occurring compound that has been shown to exert anti-inflammatory and neuroprotective effects in animal models of neurodegenerative diseases. PEA is a member of the lipoxin family of lipid mediators, which are produced by the lipoxigenase pathway and have been implicated in the resolution of inflammation.

In this study, we investigated the effects of ultramicronized PEA (um-PEA) on cognitive function, neuroinflammation, and neuropathological mechanisms in a triple transgenic mouse model of AD (3xTg-AD). We found that um-PEA improves learning and memory, and ameliorates both the depressive and anhedonia-like phenotype of 3xTg-AD mice. Moreover, um-PEA reduces Aβ formation, the phosphorylation of tau proteins, and promotes neuronal survival in the CA1 subregion of the hippocampus. Finally, um-PEA normalizes astrocytic function, rebalances glutamatergic transmission, and restrains neuroinflammation. These results suggest that um-PEA is a promising treatment for AD with the potential to be integrated into a multitargeted treatment strategy in combination with other drugs.
tangles (NFTs), whose precise role in the progression of AD remains to be clarified\textsuperscript{12}. Interestingly, preclinical and clinical data have demonstrated that both SPs and NFTs are colocalized close to activated glial cells, suggesting that a dysfunction in glia homeostasis is a key pathoge-
netic mechanism in AD\textsuperscript{3–5}. In the context of AD, both astrocytes and microglia can be activated by Aβ which promotes further reactive gliosis\textsuperscript{6}. This phenomenon is normally engaged with the intent of defending the brain by removing injurious stimuli (e.g., Aβ fibrils phagocytosis). However, if prolonged, this response exceeds normal physiological limits and can induce detrimental effects\textsuperscript{7–10}.

Our hypothesis is that an early combination of neuroprotective and anti-inflammatory treatments represents a promising treatment approach for the treatment of AD. The endogenous lipid mediator palmitoylethanolamide (PEA) demonstrates exceptional potential as a novel treatment for AD. We have previously demonstrated PEA anti-inflammatory and neuroprotective properties, as well as its ability to preserve memory function in rodent models of AD\textsuperscript{11–16}. At present, we lack precise information concerning both the effects of chronic PEA administration on the progression of AD and the optimal time to begin treatment. This is an important consideration as one of the major problems with the development of effective treatments for AD is that diagnosis is normally made at an advanced stage of the disease which may mean many therapeutic interventions begin too late to be effective.

In this paper, we evaluated the effects of chronic um-PEA administration in 3×Tg-AD mice at two different stages (mild and severe) of AD-like pathology and cognitive deficits, by subcutaneously administering the drug to two age groups of animals for 3 months. 3×Tg-AD mice were chosen because they present both Aβ deposits and tau pathology, as well as synaptic dysfunction, thus representing a widely used and validated model which closely mimics the neuropathological alterations seen in human AD\textsuperscript{17,18}. The animals were then tested using a range of cognitive and noncognitive tasks, followed by an assessment of neuropathology.

Our data demonstrate the first in vivo evidence that chronic treatment with ultramicronized-PEA (um-PEA), a formulation which maximizes its bioavailability\textsuperscript{19,20}, induces considerable improvements in cognitive and neural function during both the early presymptomatic and later symptomatic stages of AD in a triple transgenic mouse model of AD (3×Tg-AD mice).

Our data suggest that PEA demonstrates exceptional potential as a novel treatment for AD and in combination with the fact that is already licensed for the use in humans, where it demonstrates high safety and tolerability, provides an opportunity for its rapid translation in clinical practise.

**Materials and methods**

**Animals and pellet implantation**

3×Tg-AD (harboring APP\textsubscript{swes} PS1\textsubscript{M146V}, and tau\textsubscript{P301L} transgenes) male mice and their sex- and age-matched wild-type littermates (Non-Tg) (C57BL6/129SvJ) were maintained in controlled conditions (12-h light/12-h dark cycle, temperature 22 °C, humidity 50–60%, fresh food, and water ad libitum). All procedures were conducted in accordance with the guidelines of the Italian Ministry of Health (D.L. 26/2014) and the European Parliamentary directive 2010/63/EU.

Mice of 3 and 9 months were anesthetized by i.p. injection of ketamine hydrochloride (1 mg/10 g) and xylazine (0.1 mg/10 g). The area between the shoulder blades was shaved and the surgical area was sterilized with alcohol. A small (1–2 cm) dorsal midline incision was made and a subcutaneous pocket was created with a blunt probe. An um-PEA or a placebo pellet was placed into the pocket and the incision was closed with sterile sutures.

**Drugs and protocols**

Um-PEA (EPT2110/1) was obtained from Epitech America, Sarasota, Florida; cat. #NX-999) or placebo (cat. #NC-111) was subcutaneously implanted. During pellet inclusion process, um-PEA was homogeneously distributed in the matrix, maintaining its original crystalline form and micrometric size; both dosage and administration route were chosen according to previous data\textsuperscript{20,21}. Both Non-Tg and 3×Tg-AD mice were randomly assigned to either placebo or um-PEA group. No animals were excluded from the analysis. Behavioral sample size (N) is specified in open and black bars of Fig. 1. For molecular analyses, the sample size (N) for all experimental groups/condition is specified in the figure legends.

Behavioral, microdialysis/HPLC, and MRI/MSI experiments were performed as previously described\textsuperscript{22–29}, and conducted at the end of 90-day treatment. Mice were then killed, and hippocampi were isolated for western blot (WB), cytokine assays, and RT-PCR analyses, whereas whole brains for immunohistochemistry were flash-frozen in 2-methylbutane. Biochemical analyses were performed as previously described\textsuperscript{11}. The timeline of the experiments is described in Fig. 1a.

**Behavioral tests**

The minimum interval between two consecutive procedures was 2 days. All tests were performed between 8:00 a.m. and 3:00 p.m., in a dimly lit condition. On the day of testing, the mice were acclimated for about 60 min in the
Fig. 1 (See legend on next page.)
behavioral room before the procedures were initiated. Mice were weighed every day during the entire period of the experiment. All behavioral tasks were analyzed by a blinded investigator.

**Novel object recognition test (NORT)**

Each mouse was habituated to an empty Plexiglas arena (45 × 25 × 20 cm) for 3 consecutive days. On training (day 4), mice were exposed to two identical objects (A+A) placed at opposite ends of the arena for 5 min. After 30 min and 24 h, the animals were subjected to a 5-min retention session where they were exposed to one object A and to a novel object B (after 30 min) and object C (after 24 h). Exploration was considered as pointing the head toward an object at a distance of <2.5 cm from the object, with its neck extended and vibrissae moving. Turning around, chewing, and sitting on the objects were not considered exploratory behaviors. Behavior was recorded with a MV750i camera (1024 × 768 resolution, Canon, Tokyo, Japan) and scored by a blinded investigator. Videotapes were analyzed as MPEG files using a behavioral tracking system furnished with infrared lighting-sensitive CCD cameras. Animal performances were monitored with the EthoVision XT version 7 video-tracking software system (Noldus Information Technology Inc., Leesburg, VA). The time of exploration was recorded, and an object recognition index (ORI) was calculated, such that ORI = (TN−TF)/(TN + TF), where TN and TF represent times of exploring the familiar and novel object, respectively. Mice that did not explore both objects during training were discarded from further analysis.

**Inhibitory passive avoidance (IA)**

On training, mice were placed in the fear-conditioning chamber and were allowed to explore for 2 min before receiving three electric foot shocks (1 s, 0.1 mA; inter-shock interval, 2 min). Animals were returned to the home cage 30 s after the last footshock. The animals were subsequently tested 24 h or 7 days after the training phase to assess the short- and long-term memory. During this phase, the behavior in the conditioning chamber was video recorded for 5 min and subsequently was analyzed for freezing behavior, which was defined as the absence of all movements except for respiration.

**Morris water maze (MWM)**

The test was conducted in a circular tank of 1.2 m in diameter, and locates in a room with several extra maze cues. Mice were trained to swim to a 14-cm-diameter circular Plexiglas platform submerged 1.5 cm beneath the surface of water and invisible to the mouse while swimming. The water temperature was kept at 25 °C throughout the duration of the test. The platform was fixed in place, equidistant from the center of the tank and its walls. Mice were subjected to four training trials per day and were alternated among four random starting points for 5 consecutive days. Mice were allowed to find and escape onto the submerged platform. If the mice failed to find the platform within 60 s, they were manually guided to the platform and were allowed to remain on it for 10 s. After this, each mouse was placed into a holding cage under a warming lamp for 25 s until the start of the next trial. Retention of the spatial memory (the probe trial) was assessed 1.5 and 24 h after the last training session and consisted of a 60 s trial without the platform. Mice were monitored by a camera mounted in the ceiling directly above the pool, and all trials were stored on videotape for subsequent analysis. The parameters measured during the probe trial included initial latency to cross the platform location, number of platform location crosses, and time spent in the target quadrant.

**Tail suspension test (TST)**

Mice were suspended for 6 min by the tail and the duration of immobility was measured during the last 4 min.

**Forced swim test (FST)**

Mice were individually placed in a Plexiglas cylinder (20 cm diameter, 50 cm high) containing 20 cm of water (25 °C). The experiment lasted for 6 min and the duration of immobility was analyzed during the last 4 min.

**Sucrose preference test (SPT)**

Singly caged mouse had free access to two drinking bottles, the first filled with tap water, while the other with
a 2% sucrose solution. Before the test, there was a period of adaptation that lasted for 48 h. The animals were then deprived of food and liquids for 3 h. During the next 24 h, free consumption of water and 2% sucrose solution took place, in the presence of ad libitum food. Fluid intake was measured afterward by weighing the drinking bottles. The sucrose preference (%) was determined as follows: sucrose solution intake (g)/total fluid intake (g) × 100.

Biochemical testing procedures

**RNA isolation and RT-PCR**

Total RNA from hemi-hippocampi homogenates was extracted by using the NYZ total RNA isolation kit (NYZTech, Lisbon, Portugal) following the company's datasheet. The total RNA was measured by Nanodrop 1 000 spectrophotometer (Thermo Fisher Scientific, MD, USA), so, 1 µg of RNA was reverse transcribed to obtain cDNA by using oligo(dT) and random primers of the first-strand cDNA synthesis kit (NYZTech, Lisbon, Portugal). All PCRs were performed using supreme NZYTaq DNA polymerase (NYZTech, Lisbon, Portugal) with specific primers (Sigma-Aldrich, Milan, Italy) for tumor necrosis factor-α (TNF-α), forward primer 5′-CAGCCCGA TGGGTTGATCCCT-3′ and reverse primer 5′-CCGG ACTCCGCAAAGTCTAA-3′, interleukin-1β (IL-1β), forward primer 5′-GGACCCCCAAAATGAAAGGC-3′ and reverse primer 5′-GGAAAAAGAGGTGCTCA TGTC-3′, and IL-10 (forward primer 5′-GCCCTTG CTATAGGCCATGAGGTCCAC-3′) was used and reverse primer 5′-CCATGAGGCCATGAGGC-3′) was used as reference gene.

**Protein extraction and western blot analysis**

Hemi-hippocampi were homogenized in ice-cold hypotonic lysis buffer (50 mM Tris/HCl, pH 7.5, 150 mM NaCl, 1 mM ethylenediaminetetraacetic acid (EDTA), 1% triton X-100, 1 mM phenylmethylsulfonyl fluoride (PMF), 10 µg/ml aprotinin, and 0.1 mM leupeptin, all from Sigma-Aldrich, Milan, Italy) and incubated for 40 min at +4 °C. Protein dephosphorylation was avoided by adding a phosphatase inhibitor cocktail. The homogenates were then centrifuged, cellular membranes discarded, and the obtained supernatant was aliquoted and stored at −80 °C. Bradford assay was performed to calculate protein concentration. An equal amount of proteins (50 µg) was resolved on 12% acrylamide SDS-PAGE precast gels (Bio Rad Laboratories, Milan, Italy) and transferred onto nitrocellulose membranes through a semidyndry system (Bio Rad Laboratories, Milan, Italy). Membranes were blocked for 1 h either with no-fat dry milk or bovine serum albumin (BSA) powders in tris-buffered saline–0.1% tween 20 (TBS-T) (Tecnochimica, Rome, Italy).

Overnight incubation at +4 °C was performed with one of the following primary antibodies: rabbit anti-amyloid precursor protein (anti-APP 1:1 000, Cell Signaling, Danvers, MA, USA), rabbit anti-β-secretase (anti-BACE1 1:1 000, Cell Signaling, Danvers, MA, USA), mouse anti-β-amyloid (1:200, Millipore, Darmstadt, Germany), rabbit anti-Akt (1:500, Cell Signaling, Danvers, MA, USA), rabbit anti-p[Thr308]Akt (1:5 000, Cell Signaling, Danvers, MA, USA), rabbit anti-glycogen synthase kinase-3β (anti-Gsk-3β 1:1 000, Cell Signaling, Danvers, MA, USA), rabbit anti-p[Ser9]Gsk-3β (1:1 000, Cell Signaling, Danvers, MA, USA), rabbit anti-phospho Akt (anti-p[Ser473]Akt 1:1 000, Thermo Fisher Scientific, Waltham, MA, USA), mouse anti-microtubule-associated protein 2 (anti-MAP2 1:250, Novus Biologicals, Littleton, CO, USA), rabbit anti-S100B (1:1 000, Epitomics, Burlingame, CA, USA), rabbit anti-glial fibrillary acidic protein (anti-GFAP 1:2 500, Abcam, Cambridge, UK), rabbit anti-p[Ser366]nuclear factor kappa-light-chain enhancer of activated B cells (anti-p[Ser366]NF-kB 1:2 000, Cell Signaling, Danvers, MA, USA), rabbit anti-inducible nitric oxide synthase (anti-iNOS, 1:8 000, Sigma-Aldrich, Milan, Italy), rabbit anti-glutamate transporter GLT-1 (1:1 000, Tocris, Bristol, UK), and mouse anti-glutamine synthetase clone GS-6 (1:1 000, Millipore, Darmstadt, Germany). Rabbit anti-β-actin (1:1 500, Santa Cruz, Dallas, TX, USA) was used as loading control.

Membranes were incubated with a specific secondary horseradish peroxidase (HRP)-conjugated antibody (HRP-conjugated goat anti-rabbit IgG, 1:10 000–1:30 000; HRP-conjugated goat anti-mouse, 1:10 000; all from Jackson ImmunoResearch, Suffolk, UK) either in no-fat dry milk or BSA TBS-T. Immunocomplexes were detected by an enhanced chemiluminescence (ECL) kit (GE Healthcare Life Sciences, Milan, Italy) and the signal obtained was quantified by ImageJ software after densitometric scanning of the X-ray films (GE Healthcare Life Sciences, Milan, Italy).

**Immunohistochemistry**

Immunohistochemistry for GFAP and MAP2 was performed on coronal slices (12 µm thickness) containing the hippocampal regions, collected, and postfixed with 4% paraformaldehyde in 0.1 M phosphate buffer solution (PBS) (Tecnochimica, Rome, Italy). Slices were incubated with blocking solution and then incubated overnight in blocking solution containing either rabbit anti-GFAP (1:1 000, Abcam, Cambridge, UK) or mouse anti-MAP2 (1:250, Novus Biologicals, Littleton, CO, USA). Sections were incubated with the proper secondary antibody (1:200, fluorescein-afinipure goat anti-rabbit IgG (H+L); 1:300–1:400, rhodamine-afinipure goat anti-mouse IgG (H+L), Jackson ImmunoResearch, Suffolk, UK) and 4'6-diamidino-2-phenylindole (DAPI 1:75 000, Sigma-
Aldrich, Milan, Italy) in BSA at room temperature. Fluorescent signal was detected by an Eclipse E600 microscope (Nikon, Tokyo, Japan) using both Nikon Plan 10X/10.25 and Nikon Plan Fluor 20X/0.5 objectives. Pictures were captured by a QImaging camera (Canada) with NSElements BR 3.2 64-bit software with pixel resolution of 1024 × 1024.

Analysis was performed by ImageJ software and data were expressed as a ratio of the difference between the mean of fluorescence signal and the background (ΔF), and the non-immunoreactive regions (F₀). To prevent any change in the fluorescent signal due to artifacts, the gain and time exposure were kept constant during all image acquisitions.

Cytokine array

Hippocampal homogenates were analyzed for cytokines presence using a mouse cytokine array panel A (R&D Systems, Minneapolis). A total of 100 μg for each hippocampal lysate were processed following the manufacturer’s instructions.

In vivo microdialysis and HPLC analysis

In vivo microdialysis was performed in awake and freely moving mice. Anesthetized mice were stereotaxically implanted with a CMA/7 guide cannula with stylet (CMA Microdialysis, Stockholm, Sweden) into the ventral hippocampus (anterior–posterior, −3.0 mm; lateral, +3.0 mm; and ventral, −1.8 mm from bregma). Following a 2-day recovery period, the CMA/7 probe was inserted and dialyses were carried out perfusing the probe with Krebs-Ringer phosphate (KRP) buffer at flow rate of 1 μl/min. The constituents of the KRP buffer were (in mM) NaCl 145, KCl 2.7, MgCl₂ 1, CaCl₂ 2.4, and Na₂HPO₄ 2, buffered at pH 7.4. After a 2-h stabilization period, four baseline samples were collected every 20 min. Probe position was verified histologically and glutamate was quantified by HPLC coupled to fluorescence detection.

Magnetic resonance imaging (MRI)/magnetic resonance spectroscopy (MRS)

Mice of 6 and 12 months undergo MRI and MRS scanning to evaluate genotype- and treatment-induced differences in brain metabolism. Animals were anesthetized with 2.5–1.5% isoflurane (IsoFlo, Abbott SpA, Berkshire, UK) in oxygen at flow rate of 1 l/min. MRI/MRS experiments were conducted on a 4.7T Agilent Inova preclinical system (Agilent Technologies Inc., Palo Alto, CA, USA) equipped with a combination of volume and surface coils (Rapid Biomedical GmbH, Rimpar, Germany). Fast spin-echo sagittal anatomical images (Repetition Time (TR)/Echo Time (TE) = 3200/60 ms, 13 slices of 0.8-mm thickness, Field of View (FOV) 20 × 25 mm², matrix 256 × 256, 2 averages, and scan time 12 min) were acquired for positioning of the voxel for MRS. Single voxel localized 1H MR spectra (PRESS, TR/TE = 4 000/23 ms, NS = 256) were collected from hippocampus (volume 9.5 μl) according to a quantitative protocol, which includes water T2 measurements and LCModel fitting routine for spectral analysis⁹. We adopted the spectral analysis which considers Glx as the combined signal that mainly comes from glutamate plus glutamine because, at field strength generally used in human MRS studies, they have overlapping signals.

Statistical analysis

Sample size was determined on the basis of our previous experiments and by using the software GPower. All data were expressed as mean ± standard error of measurement (SEM). Behavioral, biochemical, and MRI/MRS data were analyzed by two-way analyses of variance (ANOVA) with genotype (3×Tg-AD vs Non-Tg) and treatment (um-PEA vs placebo) as between-subject factors. Tukey’s honestly significant difference (HSD) test or Bonferroni’s test were used for multiple post hoc comparisons when required. The threshold for statistical significance was set at p < 0.05.

Data availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Results

Behavioral tasks

Statistical details are reported in Table 1.

Um-PEA improves learning and memory in 6-month-old 3×Tg-AD mice

We tested the effects of um-PEA on both short (30 min) and long-term (24 h) memory with a novel object recognition test (NORT). Two-way ANOVA analysis revealed significant changes in the time mice spent exploring the new object across the four different groups. At 30 min, we found significant genotype-by-treatment interaction effects, while no significant differences were found for the main effects of genotype and treatment. Post hoc comparisons showed a significant higher object recognition index (ORI) for 3×Tg-AD mice treated with um-PEA with respect to placebo-treated 3×Tg-AD mice (Fig. 1b). Performing this trial 24 h later, we observed a significant genotype and genotype-by-treatment interaction effect of ORI in the exploration session among the four groups. Post hoc analysis demonstrated that um-PEA-treated 3×Tg-AD mice performed significantly better than the placebo-treated 3×Tg-AD group, and indicated that, at both time points, um-PEA had no effect on the performance of Non-Tg mice (Fig. 1b).
Table 1 Results from the statistical analysis of data obtained from the behavioral tests of 6- and 12-month-old mice

| Behavioral tests | Parameter                          | Genotype (G) | Treatment (T) | Interaction G X T |
|------------------|-----------------------------------|--------------|---------------|------------------|
|                  |                                   | (1,30) = 0.154, n.s. | (1,30) = 1.251, n.s. | (1,30) = 9.460, p < 0.01 |
|                  | Object recognition index—30 min   | F             | F             | F                 |
|                  | Object recognition index—24 h     | F (1,31) = 9.310, p < 0.01 | F (1,31) = 0.112, n.s. | F (1,31) = 3.431, n.s. |
| IA               | Latency to enter dark compartment—24 h | F (1,29) = 4.799, p < 0.05 | F (1,29) = 0.261, n.s. | F (1,29) = 2.189, n.s. |
|                  | Latency to enter dark compartment—7 days | F (1,29) = 1653, n.s. | F (1,29) = 0.179, n.s. | F (1,29) = 1.723, n.s. |
| MWM              | Latency to cross platform location—1.5 h | F (1,29) = 1273, n.s. | F (1,29) = 3.760, n.s. | F (1,29) = 4.326, p < 0.05 |
|                  | Latency to cross platform location—24 h | F (1,29) = 5.725, p < 0.05 | F (1,29) = 0.388, n.s. | F (1,29) = 0.464, n.s. |
|                  | Time in the target quadrant—1.5 h | F (1,29) = 3.715, p = 0.005 | F (1,29) = 3.022, p = 0.094 | F (1,29) = 3.437, p = 0.07 |
|                  | Time in the target quadrant—24 h | F (1,29) = 2.107,n.s | F (1,29) = 1.303, n.s. | F (1,29) = 1.277, n.s. |
|                  | Number of platf location crosses—1.5 h | F (1,29) = 1.783, n.s. | F (1,29) = 1.030, n.s. | F (1,29) = 6.303, p < 0.05 |
|                  | Number of platf location crosses—24 h | F (1,29) = 4.474, p < 0.05 | F (1,29) = 0.261, n.s. | F (1,29) = 0.225. n.s. |
| TST              | Immobility                        | F (1,28) = 11.873, p < 0.01 | F (1,28) = 0.363, n.s. | F (1,28) = 1.681, n.s. |
| FST              | Immobility                        | F (1,29) = 39.689, p < 0.001 | F (1,29) = 0.00321, n.s. | F (1,29) = 4.690, p < 0.05 |
| SPT              | Total fluid intake                | F (1,29) = 2.638, n.s. | F (1,29) = 0.0558, n.s. | F (1,29) = 0.733, n.s. |
|                  | Sucrose preference                | F (1,29) = 1.126, n.s. | F (1,29) = 2.319, n.s. | F (1,29) = 4.563, p < 0.05 |

Two-way analyses of variance (ANOVA) with genotype (3xTg-AD vs Non-Tg) and treatment (um-PEA vs placebo) as between-subject factors (n = 10–12 per group). Details are reported in the text.

NORT novel object recognition test, IA inhibitory passive avoidance, MWM Morris water maze, TST tail suspension test, FST forced swim test, SPT sucrose preference test.

Contextual learning and memory were then evaluated by an inhibitory passive avoidance task (IA), and the retention test was then conducted 24 h or 7 days after the training trial to assess short- and long-term memory. Statistical analysis indicated, at both time points, a significant main effect of genotype, treatment, and genotype-by-treatment interaction. Multiple post hoc comparisons indicated that um-PEA-treated transgenic mice performed better than placebo-treated 3xTg-AD mice, and reached the same performance level of Non-Tg animals (Fig. 1c). This was not due to differences in or enhanced sensitivity to the footshock, as all mice had similar jump responses upon shock administration.

Spatial learning was measured by the Morris water maze (MWM). Mice received four training trials/day for 5 consecutive days to locate the hidden platform. Statistics
Fig. 2 (See legend on next page.)
demonstrated no difference in spatial memory during 5 days of training among all groups measured (data not shown). To determine the effects of um-PEA on memory, the platform was removed from the maze, and tests were conducted 1.5 or 24 h following the last training trial to independently assess both short- and long-term memory, respectively. Um-PEA rescued the early spatial memory deficits present in 6-month-old 3×Tg-AD mice, as indicated by a significantly decreased latency to cross the platform location of the 3×Tg-AD mice treated with um-PEA compared to placebo-treated 3×Tg-AD (Fig. 1d). Moreover, the number of platform location crosses, as well as the time spent in the target quadrant were significantly increased in um-PEA-treated 3×Tg-AD compared to placebo-treated 3×Tg-AD mice. Multiple post hoc comparisons showed that 3×Tg-AD mice treated with um-PEA performed similarly to the Non-Tg mice in all probe trials and at both time points. Finally, um-PEA had no significant effects on learning or memory retention in Non-Tg mice (Fig. 1e, f).

Overall, these data indicate that um-PEA treatment rescues early learning and memory deficits in 6-month-old 3×Tg-AD mice.

**Um-PEA improves short-term learning and memory alone in 12-month-old 3×Tg-AD mice**

Two-way ANOVA for the ORI at a time point of 30 min (short memory) in 12-month-old mice revealed a significant genotype-by-treatment interaction effect, while no significant main effects of genotype and treatment were found. Multiple post hoc comparisons showed a significant higher ORI in um-PEA-treated 3×Tg-AD with respect to placebo-treated 3×Tg-AD mice (Fig. 1g).

When the probe trial was performed 24 h after the exploration session (long-term memory), we observed a significant main effect of genotype only among the four groups (Fig. 1g).

In 12-month-old mice, IA showed significant main effects only for genotype 24 h after the training trial, whereas at 7 days, no significant main effects were observed (Fig. 1h).

The results from MWM in 12-month-old mice demonstrated that no significant differences were observed during 5 days of training among the four different groups (data not shown). When the probe trial was performed 1.5 h after the last training session (short-term memory), statistical analysis showed that um-PEA significantly decreased the latency to cross the platform location and increased the number of platform location crosses in 3×Tg-AD compared to placebo-treated 3×Tg-AD mice (Fig. 1i, j). Regarding the time spent in the target quadrant at 1.5 h after the last training session, no significant differences were observed among the four groups, although um-PEA induced a trend toward an increase (+43%) in the 3×Tg-AD compared to placebo-treated 3×Tg-AD mice (Fig. 1k). Moreover, when testing was performed at 24 h after the last training session (long-term memory), statistical analysis showed a significant main effect of genotype alone for both latency to cross the platform location and the number of platform location crosses (Fig. 1l–k).

Overall, these data indicate that um-PEA improves the short-term memory of 12-month-old 3×Tg-AD mice, with no significant effects on long-term memory. Moreover, um-PEA exerts no significant effects on learning or memory in aged Non-Tg mice.

**Um-PEA ameliorates the depressive- and anhedonia-like behaviors in 3×Tg-AD mice**

Depressive-like behaviors were measured by the tail suspension test (TST) and forced swim test (FST). At 6 months of age, significant main effects of treatment, genotype, and genotype-by-treatment interactions were observed. Post hoc comparisons revealed that the immobility time in both tests was higher in placebo-treated 3×Tg-AD than in placebo-treated Non-Tg mice. Moreover, um-PEA significantly decreased the immobility time in the 3×Tg-AD for both tests (Fig. 1l, m). Interestingly, we found a significant main effect of genotype alone in 12-month-old mice, with no significant main effects of treatment and genotype-by-treatment interaction (Fig. 1l, m).

Anhedonia-like behaviors were measured by a sucrose preference test (SPT). SPT revealed a significant main effect of genotype and genotype-by-treatment interaction at 6 months of age, and other significant main effects included a genotype-by-treatment interaction at 12 months of age (Fig. 1n, o). Multiple post hoc
Fig. 3 (See legend on next page.)
comparisons demonstrated a significantly increased preference for sucrose in the placebo-treated Non-Tg mice compared to placebo-treated 3×Tg-AD mice. Interestingly, um-PEA restored the preference for the sweet solution in the 3×Tg-AD group at both 6 and 12 months of age. This effect was not accounted for by a difference in total fluid intake among all groups (Fig. 1n, o).

Altogether, these results suggest that 3×Tg-AD mice show a depressive-like phenotype that is reversed by um-PEA treatment only at 6 months of age, while no significant effect is observed at 12 months of age. Differently, um-PEA treatment attenuates the anhedonia-like phenotype of both 6- and 12-month-old 3×Tg-AD mice. Moreover, um-PEA has no significant effect on Non-Tg mice.

Um-PEA reduces Aβ formation in aged 3×Tg-AD mice

To evaluate the effect of um-PEA on AD-like pathology, we studied the expression of APP, BACE1, and Aβ (1–42). Placebo-treated 3×Tg-AD mice of 6 and 12 months compared with placebo-treated Non-Tg littermates showed a significant increase of APP and, despite no changes in BACE1 expression, exhibited a massive increase in Aβ (1–42) levels. At both ages, um-PEA did not change the expression of full-length APP. Interestingly, um-PEA strongly reduced Aβ (1–42) expression in 3×Tg-AD mice only at 12 months of age (Fig. 2a–d).

Together, these results show that chronic um-PEA treatment reduces hippocampal Aβ (1–42) expression in aging 12-month-old 3×Tg-AD mice, while inducing no significant effects in younger 6-month-old 3×Tg-AD mice.

Um-PEA reduces tau phosphorylation and promotes neuronal survival in 3×Tg-AD mice

The expression of Gsk-3β and the downstream abnormally phosphorylated (p[Ser396]tau) tau protein, both closely related to NFT formation and its associated neuronal impairments, were evaluated30–34. We also assessed the expression of the Akt, a kinase whose active form p[Thr308]Akt is responsible for Gsk-3β inactivation through Ser9 phosphorylation35. The results showed, despite no changes in the total Akt quantity, a significant decrease of p[Thr308]Akt in 6-month-old placebo-treated 3×Tg-AD mice in comparison with placebo-treated Non-Tg littermates. Although no differences in Gsk-3β total amount were detected, placebo-treated 3×Tg-AD demonstrated a significant p[Ser9]Gsk-3β reduction at both ages compared to placebo-treated Non-Tg mice. Um-PEA increased both p[Thr308]Akt and p[Ser9]Gsk-3β in 6-month-old 3×Tg-AD compared to age-matched Non-Tg mice. Moreover, in placebo-treated 3×Tg-AD mice at both ages, we observed a significant p[Ser396]tau increase that was substantively reduced by um-PEA (Fig. 2e–j).

As a consequence of these observations, we investigated neuronal survival by testing the expression of MAP2. Western blot experiments did not show any difference between expression in any of these groups at both ages (Fig. 3d, e). However, immunofluorescence experiments, which were performed to examine subtle differences in expression between different hippocampal subregions, revealed a significant increase in MAP2 immunoreactivity in the CA1 of um-PEA-treated 3×Tg-AD mice at both ages (Fig. 3a–c).

Altogether, these data suggest that um-PEA reduces abnormal tau phosphorylation in the hippocampus of 3×Tg-AD mice at 6 and 12 months of age, and that such an effect may be partially mediated by the Gsk-3β/Akt pathway. Moreover, um-PEA promotes MAP2 expression and hence neuronal survival in the CA1 subregion of the hippocampus of 3×Tg-AD mice.

Um-PEA normalizes astrocyte function and restraints neuroinflammation

We examined the effects of chronic um-PEA treatment on astrocyte function. Specifically, the expression of the cytoskeletal GFAP and S100B, a glial-derived neurotrophin whose levels are affected in AD6, was tested. We did not detect any significant difference in 6-month-old 3×Tg-AD mice compared to Non-Tg littermates in the expression of both GFAP and S100B (Fig. 4a–d, f).

We then examined the expression of a range of cytokines which revealed that 3×Tg-AD mice exhibit a transition to an increased proinflammatory state. It is notable that placebo-treated 6-month-old 3×Tg-AD mice displayed an increased transactivation of NF-κB p65 subunit, an overproduction of proinflammatory mediators,
Fig. 4 (See legend on next page.)
including iNOS, TNF-α, IL-1β, IL-16, and IL-5, macrophage colony-stimulating factor (M-CSF), monocyte chemotactic protein 5 (MCP-5), and reduction of the anti-inflammatory IL-10. Chronic treatment with um-PEA almost completely abolished the increase in inflammatory markers observed in 6-month-old 3×Tg-AD mice, and suppressed the expression of p[Ser536]p65, IL-1β, M-CSF, IL-16, MCP-5, and IL-5 but not iNOS and TNF-α, while enhancing IL-10 transcription (Fig. 5).

Contrasting results were obtained in aging animals. Indeed, placebo-treated 12-month-old 3×Tg-AD mice exhibited a significant reduction of GFAP expression compared to placebo-treated Non-Tg (Fig. 4a, b), and immunofluorescence revealed that um-PEA restored GFAP expression in the CA1 subregion of the hippocampus (Fig. 4e, f). Moreover, we did not observe any genotype-related difference in S100B expression. Interestingly, um-PEA significantly decreased S100B levels in both genotypes (Fig. 4a, c). Finally, in 12-month-old mice, we did not detect a transition to a proinflammatory state. However, at this age, um-PEA reduced iNOS expression in 3×Tg-AD, and enhanced IL-10 transcript in Non-Tg (Fig. 5a, c, l, m).

Collectively, these results show that 6-month-old 3×Tg-AD mice exhibit mild astrocyte activation but displayed an intense inflammatory status. In contrast, 12-month-old 3×Tg-AD mice did not demonstrate astrocyte activation but a slight astrocyte atrophy not accompanied by neuroinflammation. Um-PEA stabilizes the altered parameters related to astrocyte function, bringing them to more physiological levels, and restraints neuroinflammation.

**Um-PEA effect on glutamatergic transmission**

Quantitative magnetic resonance spectroscopy (MRS) analyses demonstrated that 6-month-old 3×Tg-AD mice had reduced hippocampal levels of both Glx (a combined measure of glutamate and glutamine) and N-acetylaspartate (NAA) compared to age-matched Non-Tg littermates. Interestingly, um-PEA significantly increased Glx levels only in the 3×Tg-AD mice (Fig. 6a-d). As Glx concentration reflects both intracellular and extracellular glutamate and glutamine pools, we attempted to gain deeper insights into the functional state of glutamatergic transmission by microdialysis. The results showed that basal extracellular glutamate levels in the hippocampus of 6-month-old 3×Tg-AD were significantly higher compared to age-matched Non-Tg mice (Fig. 6e). Western blot analyses indicated that the higher extracellular glutamate levels in transgenic mice may be partially due to the reduced expression of GLT-1, while the expression of GS remained unaffected (Fig. 6f-i). Even though our results were not statistically significant, um-PEA treatment induced a trend toward an increase of GLT-1 (+35%) in 6-month-old 3×Tg-AD mice compared to placebo-treated Non-Tg ones (Fig. 6g, h).

In 12-month-old mice, we did not record any genotype-related differences in Glx, NAA, or extracellular glutamate levels despite a reduction in GLT-1 being evident (Fig. 6). Collectively, these results indicate that 6-month-old 3×Tg-AD mice exhibit a disruption to glutamatergic function and that um-PEA increases Glx levels.

**Discussion**

This study, employing a multidisciplinary approach, provides compelling evidence that a chronic um-PEA treatment exerts anti-inflammatory and neuroprotective effects in a murine model of AD that recapitulates the salient neural and cognitive impairments seen in this disease. It also demonstrates that um-PEA exerts these effects in both mildly declining young (6-month-old) and severely declining aging (12-month-old) 3×Tg-AD mice, which suggests its potential to arrest the decline in neural and cognitive function at two separate stages of the disease. These data also provide novel insights into the molecular mechanisms involved in AD. We comprehensively examined a number of pathways underlying astrocyte function, neuroinflammation, and neuronal integrity in 6- and 12-month-old 3×Tg-AD mice chronically receiving um-PEA or placebo for 3 months. Our results confirm that important behavioral and molecular modifications occur during the early stages of AD, and demonstrate that chronically administered um-PEA restrains or reverses most of them.

These results are important as AD has important public health and economic consequences and there is a need to develop novel effective therapeutic strategies to complement or replace those in current use. It has been apparent...
Fig. 5 (See legend on next page.)
for a long time that PEA displays marked anti-inflammation properties in peripheral inflammation models and it has demonstrated high effectiveness in a number of neurodegenerative disorders that present with an inflammatory component, including AD, Parkinson’s disease, and multiple sclerosis\cite{10,14,36,37}. The recent availability of um-PEA, a crystalline form on micrometric size which improves both its pharmacokinetics and bioavailability\cite{19,36}, prompted us to test its anti-inflammatory and neuroprotective effects in 3xTg-AD mice.

First, we found that um-PEA rescued the early hippocampal, cortex, and amygdala-dependent memory impairments seen in 3xTg-AD mice. The youngest mice (6-month old) demonstrated the largest significant improvement of both short- and long-term memory. Less clear-cut effects were seen in the oldest mice (12-month old), where um-PEA improved short-term memory (or at least some behavioral parameters, e.g., ORI, and latency and number of crosses in the MWM), but did not induce significant effects on long-term memory. This study also demonstrates that um-PEA induces other noncognitive effects that are relevant to AD. In this regard, following the observation that a depressive-like phenotype is present in the same strain of 18-month-old 3xTg-AD mice\cite{24}, we identified that this phenotype is already present by 6 months of age and is reversible at 6 but not at 12 months of age. However, we found that um-PEA attenuates a similar anhedonia-like phenotype of both young (6-month-old) and aging (12-month-old) 3xTg-AD mice.

It is widely accepted that glia mediate the response to several brain injuries, including the deposition of A\textsubscript{β}, and undergo important morphological and functional changes that can, in turn, influence the progression of the disease. These modifications are intricate and heterogeneous, and can be crudely classified into hyperreactivity or atrophy\cite{19,40}. Moreover, a direct correlation has been established between glial dysfunction and the induction of proinflammatory pathways\cite{41}. In younger mice, although we did not detect significant alterations of GFAP and S100B, the best-known markers of astrocytic activation, we found that a range of parameters suggesting an increase in neuroinflammation occurred. These were reduced by um-PEA, suggesting that it restrains the transition to a neuroinflammatory environment. A comparison of results suggests that um-PEA effects are completely different in 3xTg-AD mice at 6 and 12 months of age. At 12 months, mice do not show any noteworthy signs of neuroinflammation and merely displayed moderate astrocyte atrophy.

Based on our results and the hypothesis that neuroinflammation accelerates the development of the AD phenotype, increasing A\textsubscript{β} accumulation, we explored the main elements involved in the pro-amyloidogenic pathway\cite{42}. 3xTg-AD mice express a mutant APP\textsubscript{swe} transgene, and we recorded an accumulation of this protein in these mice at both 6 and 12 months. No accumulation of BACE1 protein occurred, however, a 15-fold higher increase in A\textsubscript{β}(1–42) expression was observed in the 3xTg-AD compared to Non-Tg mice. Our results demonstrated the ability of um-PEA to strongly suppress A\textsubscript{β}(1–42) expression in 12-month-old 3xTg-AD mice, suggesting an important pathway by which it can restrain the disease progression. Another iconic hallmark of AD is the formation of NFTs which are mainly caused by the abnormal phosphorylation of tau. Tau protein is a microtubule-associated protein that facilitates microtubule assembly and stabilization as a function of its phosphorylation state\cite{30}. However, under pathological conditions, including AD, enhanced phosphorylation (known as “hyperphosphorylation”) occurs, which leads to microtubule dissociation, aggregation into paired helical filaments, and the subsequent production of insoluble NFTs\cite{43,44}. These events worsen axonal transport and synaptic function, which facilitates the development of a neurotoxic environment and cognitive impairments\cite{31,32}. Several kinases add phosphate groups to tau-specific amino acids and Gsk-3\textbeta is one of the primary kinases that are involved\cite{30} and its activity is regulated by Akt, a serine/threonine-specific kinase\cite{34}. We observed significant alterations of

\begin{figure}
\centering
\includegraphics[width=\textwidth]{figure5}
\caption{Um-PEA effects on neuroinflammation in hippocampus of 3xTg-AD and Non-Tg mice. Evaluation of proinflammatory markers in hippocampi of 6- and 12-month-old 3xTg-AD and age-matched Non-Tg mice chronically treated with placebo (open bars) or um-PEA (black bars). (a) Representative western blots for pSer536p65 and iNOS proteins and (b, c) densitometric analyses normalized with β-actin used as loading controls. Results are expressed as percentage of control (Non-Tg/placebo groups) (N = 3, in triplicate). (d, e) Representative results obtained from RT-PCR in 6-month-old mice for tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β), and (f, g) densitometric analysis of corresponding bands normalized with glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Results are expressed as percentage of control (Non-Tg/placebo groups) (N = 3, in triplicate). (h–k) Densitometric analysis of cytokine array for IL-16, IL-5, macrophage colony-stimulating factor (M-CSF), and monocyte chemotactic protein 5 (MCP-5). Results are expressed as percentage of control (Non-Tg/placebo groups) (N = 3, in triplicate). (l) Representative results obtained from RT-PCR in 6- and 12-month-old mice for IL-10 and (m) densitometric analysis of corresponding bands normalized with glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Results are expressed as percentage of control (Non-Tg/placebo groups) (N = 3, in triplicate). The data are presented as mean ± SEM. Statistical analysis was performed by two-way ANOVA followed by Bonferroni’s multiple-comparison test (*p < 0.05; **p < 0.01; ***p < 0.001)}
\end{figure}
Fig. 6 (See legend on next page.)
the Akt/Gsk-3β pathway in 3×Tg-AD mice, at both mild (6-month-old) and severe (12-month-old) stages of pathology, and have also demonstrated for the first time in an in vivo model the ability of um-PEA to prevent such alterations, thus reducing the abnormal phosphorylation of tau. Besides the deposition of NFTs, it has been demonstrated that a disruption of astrocyte function contributes to neuronal death. In this study, we also investigated the expression of the neuron-specific cytoskeletal marker, MAP2. By immunofluorescence, we show that um-PEA increases MAP2 expression in the CA1 zone of the hippocampus in 3×Tg-AD mice at 6 and 12 months of age, suggesting that um-PEA increases neuronal viability in this region, a key area for the mediation of memory formation and recall.

Alterations in both the glutamatergic system and the metabolism of the brain are well documented in AD patients. Employing both in vivo MRI/MRS scanning and microdialysis sampling, we evaluated the effects of um-PEA on neural metabolism and glutamatergic transmission in the hippocampus of mice. MRI/MRS revealed that 6-month-old 3×Tg-AD mice show a robust reduction of both Glx and NAA content compared to Non-Tg mice. This observation may underlie the substantial cognitive deficits observed at this age. Interestingly, um-PEA increased Glx content and improved the cognitive performance and behavioral abnormalities observed in 3×Tg-AD mice. Our data also highlight some intriguing potential mechanisms by which AD affects glutaminergic transmission. In younger (6-month-old) 3×Tg-AD mice, we observed a marked increase in the levels of extracellular glutamate, which is probably due to a reduced expression of a glial transporter mainly responsible for glutamate reuptake (GLT-1). Despite observing a similar trend in aging (12-month-old) mice, we did not detect any statistical difference in brain metabolites and extracellular glutamate levels, but a reduction of GLT-1 expression was still evident.

Our data extend the knowledge of the mechanisms underlying the progression of AD-like pathology in 3×Tg-AD mice and demonstrate the exceptional therapeutic potential of um-PEA in restraining the development of AD-like pathology and cognitive/behavioral declines by exerting a combination of anti-inflammatory and neuroprotective effects. Given the numerous and multitargeted effects of um-PEA that we observed, we can speculate that many molecular mechanisms are involved in mediating the actions of this compound. Despite we have already demonstrated, in other preclinical models of AD, that PEA exerts its pharmacological effects through the peroxisome proliferator-activated receptors alpha (PPARα) involvement, other molecular targets should be taken into account, including PPARγ, transient receptor potential vanilloid type-1 channel, orphan G-protein-coupled receptor 55, and the so-called entourage effect on the endocannabinoid system. Therefore, further experiments will be needed to address this issue. Our results indicate an interesting interaction of um-PEA treatment and the aging process, which may suggest its use as a potential preventive therapy. In aging mice, um-PEA treatment induces an effect on pathways involved in AD pathology, but the most interesting data were derived from younger mice. Indeed, changes in neural function in mice precociously treated with um-PEA (starting from 3 months of age, before any overt signs of disease) seemed to be less pronounced, suggesting the benefits of starting drug treatment at an early stage.

From the perspective of the translational potential of um-PEA in human AD, our data strongly suggest its exceptional potential as a therapy that provides clinically considerable benefits if started early enough in the continuum toward dementia. It is noteworthy that PEA, which is already licensed for use in humans, displays a high tolerability and safety profile and would be an ideal candidate for long-term use lasting several years, as potential AD treatments require. Summarizing, our data suggest that um-PEA exerts a robust therapeutic effect in a transgenic mouse model (3×Tg-AD) of AD, since it ameliorates both cognitive deficits and a range of neuropathological features. Despite
the limits of our preclinical experimental study and avoiding any simplistic extrapolation of data from the animal model to the human condition, the results of this research suggest that um-PEA demonstrates considerable potential to have an impact on the progression of AD.

Acknowledgements
This work was supported by the Italian Ministry of Instruction, University, and Research (MIUR) to LS, and the SAPIENZA University of Rome to CS and MRB.

Author details
1Department of Physiology and Pharmacology; 2V. Ersparim, SAPIENZA University of Rome, Rome, Italy; 3Department of Clinical and Experimental Medicine, University of Foggia, Foggia, Italy; 4Department of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy; 5C. U. L. Institute of Ophthalmology, University College, University College London, London, UK; 6C. U. R. E. Centre for Liver Diseases Research and Treatment, Institute of Internal Medicine, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy; 7Department of Cell Biology and Neurosciences, Istituto Superiore di Sanità, Rome, Italy; 8Department of Psychiatry, University of Naples SUN, Naples, Italy

Conflict of interest
The authors declare that they have no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 3 November 2017 Accepted: 13 November 2017
Published online: 31 January 2018

References
1. Huang, H. C. & Jiang, Z. F. Accumulated amyloid-beta peptide and hyperphosphorylated tau protein: relationship and links in Alzheimer’s disease. J. Alzheimers Dis. 16, 15–27 (2009).
2. Querfurth, H. W. & LaFerla, F. M. Alzheimer’s disease. N. Engl. J. Med. 362, 329–344 (2010).
3. Craft, J. M., Watterson, D. M. & Van Eldik, L. J. Human amyloid beta-induced neuroinflammation is an early event in neurodegeneration. Glia 53, 484–490 (2006).
4. McGeer, P. L. & McGeer, E. G. The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy. Acta Neuropathol. 126, 479–497 (2013).
5. O’donn, L. M., Kamphuis, W., Wadman, W. J. & Hol, E. M. Astroglisis: An integral player in the pathogenesis of Alzheimer’s disease. Prog. Neurobiol. 144, 121–141 (2016).
6. Verkhovsky, A. et al. Neurological diseases as primary gliopathies: a reassessment of neurocentrism. ASN Neuro 4, e00082 (2012).
7. Burda, J. E. & Sofroniew, M. V. Reactive gliosis and the multicellular response to CNS damage and disease. Neuron 81, 229–248 (2014).
8. Steardo, L. et al. Does neuroinflammation turn on the flame in Alzheimer’s disease? Focus on astrocytes. Front. Neurosci. 9, 259 (2015).
9. Verkhovsky, A., Okland, M., Nornes, H. N., Yeh, C. Y. & Rodrigues, J. J. Astrocytes in Alzheimer’s disease. Neurotherapeutics 7, 399–412 (2010).
10. Bronzuzzi, M. R., Facchinetti, R., Steardo, L. & Scuderi, C. Astrocyte: an innovative approach for Alzheimer’s disease therapy. Curr. Pharm. Des. (2017) https://doi.org/10.2174/1381612823666170710163411.
11. Scuderi, C. et al. Palmitoylethanolamides counteracts reactive astrogliosis induced by beta-amyloid peptide. J. Cell Mol Med 15, 2664–2674 (2011).
12. Scuderi, C. et al. Palmitoylethanolamides controls reactive gliosis and exerts neuroprotective functions in a rat model of Alzheimer’s disease. Cell Death Dis. 5, e1419 (2014).
13. Scuderi, C. et al. Palmitoylethanolamide exerts neuroprotective effects in mixed neuronal cultures and organotypic hippocampal slices via peroxisome proliferator-activated receptor-alpha. J. Neuroinflamm. 9, 49 (2012).
14. D’agostino, G. et al. Palmitoylethanolamide protects against the amyloid-beta-induced learning and memory impairment in mice, an experimental model of Alzheimer disease. Neuropharmacol 37, 1784–1792 (2012).
15. Tomasini, M. C. et al. Differential effects of palmitoylethanolamide against amyloid-beta toxicity in cortical neuronal and astrocytic primary cultures from wild-type and 3xTg-AD mice. J. Alzheimers Dis. 46, 407–421 (2015).
16. Bronzuzzi, M. R. et al. Palmitoylethanolamide impairs reactive astrogliosis and improves neuronal trophic support in a triple transgenic model of Alzheimer’s disease: in vitro and in vivo evidence. OXAD Med Cell Longev. (Article id: 4720532) Accepted 23 October 2017 (2017).
17. Oddo, S. et al. Triple-transgenic model of Alzheimer’s disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39, 409–421 (2003).
18. Blázquez Get al. Modeling behavioral and neuronal symptoms of Alzheimer’s disease in mice a role for intraneuronal amyloid. Neurosci. Biobehav. Rev. 31,125–127(2007).
19. Tomasini, M. C. et al. Differential effects of palmitoylethanolamide against amyloid-β toxicity in cortical neuronal and astrocytic primary cultures from wild-type and 3xTg-AD mice. J. Alzheimers Dis. 46, 407–421 (2015).
20. Grillo, S. L., Keereetaweep, J., Grillo, M. A., Chapman, K. D. & Koulou, P. N. Palmitoylethanolamine depot injection increased its tissue levels and those of other acyl ethanolamides lipids. Drug. Des. Devel Ther. 7, 747–752 (2013).
21. Costa, B., Conti, S., Gagnoni, G. & Colleoni, M. Therapeutic effect of the neuroprotective functions in a rat model of Alzheimer disease. Neurobiol. Aging 33, 1121–16 (2012).
38. Impellizzeri, D. et al. Micronized/ultramicronized palmitoylethanolamide displays superior oral efficacy compared to nonmicronized palmitoylethanolamide in a rat model of inflammatory pain. *J. Neuroinflamm.* **11**, 136 (2014).
39. Rodríguez, J. J., Olabarria, M., Chvatal, A. & Verkhratsky, A. Astroglia in dementia and Alzheimer’s disease. *Cell. Death Differ.* **16**, 378–385 (2009).
40. Verkhratsky, A. & Parpura, V. Astrogliopathology in neurological, neurodevelopmental and psychiatric disorders. *Neurobiol. Dis.* **85**, 254–261 (2016).
41. Oire, M. et al. Isolation of glia from Alzheimer’s mice reveals inflammation and dysfunction. *Neurobiol. Aging* **35**, 2746–2760 (2014).
42. Wozniak, M. A., Itzhaki, R. F., Shipley, S. J. & Dobson, C. B. Herpes simplex virus infection causes cellular beta-amyloid accumulation and secretase upregulation. *Neurosci. Lett.* **429**, 95–100 (2007).
43. De Ferrari, G. V. & Inestrosa, N. C. Wnt signaling function in Alzheimer’s disease. *Brain. Res. Rev.* **33**, 1–12 (2000).
44. Li, H. L. et al. Phosphorylation of tau antagonizes apoptosis by stabilizing beta-catenin, a mechanism involved in Alzheimer’s neurodegeneration. *Proc. Natl. Acad. Sci. USA* **104**, 3591–3596 (2007).
45. Graff-Radford, J. & Kantarci, K. Magnetic resonance spectroscopy in Alzheimer’s disease. *Neuropsychiatr. Dis. Treat.* **9**, 687–696 (2013).
46. Verkhratsky, A., Steardo, L., Peng, L. & Parpura, V. Astroglia, glutamatergic transmission and psychiatric diseases. *Adv. Neurobiol.* **13**, 307–326 (2016).
47. Scuderi, C. & Steardo, L. Neuroglial roots of neurodegenerative diseases: therapeutic potential of palmitoylethanolamide in models of Alzheimer’s disease. *CNS Neurol. Disord. Drug. Targets* **12**, 62–69 (2013).